Literature DB >> 11697751

Prednisolone pharmacokinetics and pharmacodynamics in relation to sex and race.

M H Magee1, R A Blum, C D Lates, W J Jusko.   

Abstract

Prednisolone pharmacokinetics (PK) and pharmacodynamics (PD) were investigated in relation to sex and race in white males, black males, white females, and black females (n = 8/group) after a single oral dose (0.27 mg/kg) of prednisone. The study consisted of baseline and prednisone phases with 32-hour sampling in each phase. Women were studied during the luteal phase of their menstrual cycle. Total and free plasma prednisolone concentrations were assayed by HPLC and ultrafiltration, and pharmacokinetic data were analyzed by compartmental fitting using WinNonlin. Plasma cortisol concentrations were assayed by HPLC; T-helper, T-suppressor lymphocyte, and neutrophil cell counts were determined by FACS and hemocytometry, and these pharmacodynamic data were evaluated by basic and extended indirect response models using ADAPT II. Total body weight-normalized free prednisolone oral clearance and apparent volume of distribution were higher in men compared with women, regardless of race (by 22% in whites and 40% in blacks for oral clearance, p < 0.01; by32% in whites and 38% in blacks for apparent volume of distribution, p < 0.01). The 50% inhibitory concentration (IC50) values for T-suppressor cell-trafficking inhibition were higher in whites than in blacks, regardless of sex (by 125% in men and 208% in women, p < 0.01). The IC50 or SC50 values for effects of prednisolone on cortisol secretion and T-helper lymphocyte or neutrophil trafficking were not statistically different between men and women, blacks and whites. The findings of this study suggest that there are some prednisolone PK/PD differences related to sex and race. However, these differences do not suggest the need for dosage adjustments, and additional experiments with repeat dosing are needed to fully evaluate the clinical implication of these findings.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11697751      PMCID: PMC4207281          DOI: 10.1177/00912700122012733

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  43 in total

1.  Precursor-dependent indirect pharmacodynamic response model for tolerance and rebound phenomena.

Authors:  A Sharma; W F Ebling; W J Jusko
Journal:  J Pharm Sci       Date:  1998-12       Impact factor: 3.534

Review 2.  Influence of race or ethnicity on pharmacokinetics of drugs.

Authors:  J A Johnson
Journal:  J Pharm Sci       Date:  1997-12       Impact factor: 3.534

3.  Corticosteroid analysis in biological fluids by high-performance liquid chromatography.

Authors:  J Q Rose; W J Jusko
Journal:  J Chromatogr       Date:  1979-03-01

4.  Pharmacoimmunodynamic interactions of interleukin-10 and prednisone in healthy volunteers.

Authors:  A Chakraborty; R A Blum; D L Cutler; W J Jusko
Journal:  Clin Pharmacol Ther       Date:  1999-03       Impact factor: 6.875

5.  Circadian changes of T lymphocyte subsets in human peripheral blood.

Authors:  T Miyawaki; K Taga; T Nagaoki; H Seki; Y Suzuki; N Taniguchi
Journal:  Clin Exp Immunol       Date:  1984-03       Impact factor: 4.330

6.  Variation in natural killer activity in peripheral blood during the menstrual cycle.

Authors:  A N Sulke; D B Jones; P J Wood
Journal:  Br Med J (Clin Res Ed)       Date:  1985-03-23

7.  Diurnal sleep/wake-related immune functions during the menstrual cycle of healthy young women.

Authors: 
Journal:  J Sleep Res       Date:  1995-09       Impact factor: 3.981

8.  Increased PGE2 from human monocytes isolated in the luteal phase of the menstrual cycle. Implications for immunity?

Authors:  C A Leslie; D P Dubey
Journal:  Prostaglandins       Date:  1994-01

9.  Urinary 6 beta-hydroxyprednisolone excretion indicates enhanced prednisolone catabolism.

Authors:  F J Frey; B M Frey
Journal:  J Lab Clin Med       Date:  1983-04

10.  Pharmacokinetics and pharmacodynamic modeling of direct suppression effects of methylprednisolone on serum cortisol and blood histamine in human subjects.

Authors:  A N Kong; E A Ludwig; R L Slaughter; P M DiStefano; J DeMasi; E Middleton; W J Jusko
Journal:  Clin Pharmacol Ther       Date:  1989-12       Impact factor: 6.875

View more
  31 in total

Review 1.  Sex differences in transplantation.

Authors:  Jeremiah D Momper; Michael L Misel; Dianne B McKay
Journal:  Transplant Rev (Orlando)       Date:  2017-02-20       Impact factor: 3.943

2.  Population Pharmacokinetics of Vamorolone (VBP15) in Healthy Men and Boys With Duchenne Muscular Dystrophy.

Authors:  Panteleimon D Mavroudis; John van den Anker; Laurie S Conklin; Jesse M Damsker; Eric P Hoffman; Kanneboyina Nagaraju; Paula R Clemens; William J Jusko
Journal:  J Clin Pharmacol       Date:  2019-02-11       Impact factor: 3.126

Review 3.  How do I manage hyperglycemia/post-transplant diabetes mellitus after allogeneic HSCT.

Authors:  S Fuji; A Rovó; K Ohashi; M Griffith; H Einsele; M Kapp; M Mohty; N S Majhail; B G Engelhardt; A Tichelli; B N Savani
Journal:  Bone Marrow Transplant       Date:  2016-04-04       Impact factor: 5.483

Review 4.  Transitioning from Basic toward Systems Pharmacodynamic Models: Lessons from Corticosteroids.

Authors:  Vivaswath S Ayyar; William J Jusko
Journal:  Pharmacol Rev       Date:  2020-04       Impact factor: 25.468

5.  Evaluation of limited sampling strategies for total and free prednisolone in adult kidney transplant recipients.

Authors:  Katherine A Barraclough; Nicole M Isbel; Brett C McWhinney; Jacobus P J Ungerer; Gregory Medley; David W Johnson; Carmel M Hawley; Diana R Leary; Scott B Campbell; Christine E Staatz
Journal:  Eur J Clin Pharmacol       Date:  2011-06-09       Impact factor: 2.953

6.  Comparison of the influence of cyclosporine and tacrolimus on the pharmacokinetics of prednisolone in adult male kidney transplant recipients.

Authors:  Troels K Bergmann; Nicole M Isbel; Katherine A Barraclough; Scott B Campbell; Brett C McWhinney; Christine E Staatz
Journal:  Clin Drug Investig       Date:  2014-03       Impact factor: 2.859

7.  Modeling the influence of chronopharmacological administration of synthetic glucocorticoids on the hypothalamic-pituitary-adrenal axis.

Authors:  Rohit T Rao; Megerle L Scherholz; Ioannis P Androulakis
Journal:  Chronobiol Int       Date:  2018-07-30       Impact factor: 2.877

Review 8.  Management of hyperglycemia in hospitalized patients with renal insufficiency or steroid-induced diabetes.

Authors:  David Baldwin; Jill Apel
Journal:  Curr Diab Rep       Date:  2013-02       Impact factor: 4.810

9.  Interactions of prednisolone and other immunosuppressants used in dual treatment of systemic lupus erythematosus in lymphocyte proliferation assays.

Authors:  Mohamed A Kamal; William J Jusko
Journal:  J Clin Pharmacol       Date:  2004-09       Impact factor: 3.126

10.  Pharmacokinetic/pharmacodynamic models for the depletion of Vbeta5.2/5.3 T cells by the monoclonal antibody ATM-027 in patients with multiple sclerosis, as measured by FACS.

Authors:  Per-Henrik Zingmark; Charlotte Edenius; Mats O Karlsson
Journal:  Br J Clin Pharmacol       Date:  2004-10       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.